A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

NCT04600817 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed Glioblastoma

Interventions

DRUG: TJ107
DRUG: TJ107 placebo

Sponsor

TJ Biopharma Co., Ltd.